Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SGLT2 Inhibition With Empagliflozin in Patients With Type 2 Diabetes Mellitus: Influences on Left Ventricular Mass, Function, and Cardiac Lipid Content

NCT02728453 is registered in ClinicalTrials.gov with Hannover Medical School as lead sponsor.

NCT NCT02728453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02728453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SGLT2 Inhibition With Empagliflozin in Patients With Type 2 Diabetes Mellitus: Influences on Left Ventricular Mass, Function, and Cardiac Lipid Content
Lead sponsor
Hannover Medical School
Phase
Phase 4
Overall status
Terminated
Start date
April 27, 2016
Completion date
September 27, 2017
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus type 2